Sionna Therapeutics, Inc. Common Stock

Sionna Therapeutics shares plunged more than 90% after its lead cystic fibrosis drug candidate SION-719 failed a Phase 2a trial, while Vertex Pharmaceuticals surged to new highs as a key competitive threat was removed. The trial, which tested SION-719 as an add-on to Vertex’s blockbuster Trikafta regimen, did not meet its main activity endpoint, and Sionna will not advance the program. Sionna will now prioritize an earlier-stage SION-451 combo program, but with over $268 million in cash and its lead asset shelved, the stock’s valuation was heavily dependent on SION-719. Vertex, already trading near record levels after raising full-year revenue guidance and proposing a $10 billion acquisition of Crinetics Pharmaceuticals, saw its cystic fibrosis dominance further de-risked.

Several stocks made significant midday moves on Monday. MarineMax soared 46% after agreeing to be sold to Blackstone Infrastructure's Safe Harbor Marinas for $53 a share in cash, or $1.5 billion, with the deal expected to close by the end of 2026. Varex Imaging climbed 48% after Teledyne Technologies agreed to buy the imaging component maker for $18.90 a share in cash, a deal expected to close in early 2027. Sionna Therapeutics collapsed 92% after its cystic fibrosis drug failed to meet key endpoints in a proof-of-concept trial, and the company said it would not advance the drug. Other notable movers included NetApp, which gained 6% after Morgan Stanley upgraded it to equal weight from underweight, and Verisk Analytics, which tumbled more than 5% after a Delaware judge ruled it must proceed with a $2.35 billion acquisition of AccuLynx. Apple dipped 2% after Jefferies downgraded the stock to underperform from hold, citing canceled plans for an all-glass iPhone. Intel fell nearly 3% after announcing a $15 billion common stock offering for general corporate purposes.

Vertex Pharmaceuticals shares surged approximately 5.9% in Monday's regular session after Sionna Therapeutics announced its drug SION-719 missed the key activity endpoint in a Phase 2a trial when added to the current standard of care. Sionna is dropping that specific add-on strategy, giving Vertex's dominant cystic-fibrosis franchise more breathing room. Vertex's second-quarter revenue climbed 12% to roughly $3.33 billion, and management raised full-year revenue guidance to $13.1 billion to $13.2 billion. Despite the stock's jump, GuruFocus estimates Vertex's GF Value at $519.20, leaving the shares trading only 1.34% above that fair value estimate at $526.15.

Tenax Therapeutics and Sionna Therapeutics shares plunged in premarket trading after their respective clinical trials failed, while MarineMax jumped on a reported buyout by Blackstone-owned Safe Harbor Marinas. Tenax stock fell 84.2% after its Phase 3 LEVEL trial of TNX-103 missed its primary endpoint, showing no statistically significant improvement in six-minute walk distance versus placebo with a p-value of 0.63. Sionna shares dropped 92.1% after its Phase 2a trial of SION-719 failed to demonstrate meaningful CFTR function improvement, with a placebo-adjusted sweat chloride change of just -1.0 mmol/L and a p-value of 0.7. MarineMax surged more than 34% after Reuters reported Safe Harbor is close to acquiring the boat retailer for $1.5 billion including debt, or about $53 per share in cash, a substantial premium to Friday's close of $35.68. AAON gained over 10.6% after its second-quarter results apparently beat expectations, while Silence Therapeutics rose 16.2% ahead of a conference call on its Phase 2 SANRECO trial. Dole fell 4.2% after missing second-quarter earnings and revenue estimates, and AirSculpt Technologies dropped 18.4% on weaker quarterly results with revenue down 3% year-over-year.